SEARCH

SEARCH BY CITATION

References

  • 1
    Skoner DP. Allergic rhinitis. definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001: 108 (1 Suppl): S28.
  • 2
    Stuck BA, Czajowski J, Hagner AE, Klimek L, Verse T, Hörmann K, Maurer JT. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol 2004; 113: 6638.
  • 3
    Crystal-Peters J, Crown WH, Goetzel RZ, Schutt DC. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000; 6: 3738.
  • 4
    Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, Hindmarch I, Simons ER, Spangler DL, Szefler SJ, Terndrup TE, Waldman SA, Weiler J, Wong DF. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003; 111: S83542.
  • 5
    Gillard M, Christophe B, Wels B, Peck M, Massingham R, Chatelain P. H1 antagonists: receptor affinity versus selectivity. Inflamm Res 2003; 52(Suppl 1): S4950.
  • 6
    Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32: 15049.
  • 7
    Fujikura T. New therapeutic approaches to the treatment of nasal allergy. Antiinflammatory effects of H (1) receptor antagonists. Drugs Today (Barc) 2001; 37: 45561.
  • 8
    Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002; 88: 1907.
  • 9
    Day JH, Briscoe MP, Rafeiro E, Ratz JD. Comparative Clinical Efficacy, Onset and Duration of Action of Levocetirizine and Desloratadine for Symptoms of Seasonal Allergic Rhinitis in Subjects Evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract 2004; 58: 10918.
  • 10
    Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol 2003; 112: S6977.
  • 11
    Horak F, Stübner P, Zieglmayer R, Kavina A, Vos CD3, Burtin B, Donnelly F. Controlled comparison of the efficacy and safety of cetirizine 10mg o.d. & fexofenadine 120mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001; 125: 739.
  • 12
    Stübner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR. randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit – the Vienna Challenge Chamber (VCC). Curr Med Res Opinion 2004; 20: 891902.
  • 13
    Larbig M, Stamm H, Hohlfeld J, Krug N. Levocetirizine but not desloratadine inhibits histamine-induced changes of nasal temperature measured by facial thermography: a pilot study. EAACI 2003 Abstract Book pharma service GmbH, 2003, p. 283.
  • 14
    Larbig M, Stamm H, Casper A, Hohlfeld J, Krug K. Twenty-four hour anti-H1 activity of levocetirizine measured by thermography is superior to fexofenadine. EAACI 2004 Abstract Book pharma service documediaS GmbH, 2004, p. 80.